In vivo kinetics of SARS-CoV-2 infection and its relationship with a person's infectiousness.


Journal

Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876

Informations de publication

Date de publication:
07 12 2021
Historique:
accepted: 25 10 2021
entrez: 3 12 2021
pubmed: 4 12 2021
medline: 15 12 2021
Statut: ppublish

Résumé

The within-host viral kinetics of SARS-CoV-2 infection and how they relate to a person's infectiousness are not well understood. This limits our ability to quantify the impact of interventions on viral transmission. Here, we develop viral dynamic models of SARS-CoV-2 infection and fit them to data to estimate key within-host parameters such as the infected cell half-life and the within-host reproductive number. We then develop a model linking viral load (VL) to infectiousness and show a person's infectiousness increases sublinearly with VL and that the logarithm of the VL in the upper respiratory tract is a better surrogate of infectiousness than the VL itself. Using data on VL and the predicted infectiousness, we further incorporated data on antigen and RT-PCR tests and compared their usefulness in detecting infection and preventing transmission. We found that RT-PCR tests perform better than antigen tests assuming equal testing frequency; however, more frequent antigen testing may perform equally well with RT-PCR tests at a lower cost but with many more false-negative tests. Overall, our models provide a quantitative framework for inferring the impact of therapeutics and vaccines that lower VL on the infectiousness of individuals and for evaluating rapid testing strategies.

Identifiants

pubmed: 34857628
pii: 2111477118
doi: 10.1073/pnas.2111477118
pmc: PMC8670484
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIH HHS
ID : R01 OD011095
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI152703
Pays : United States
Organisme : NIH HHS
ID : R01 AI15270301
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI028433
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI116868
Pays : United States

Commentaires et corrections

Type : UpdateOf

Informations de copyright

Copyright © 2021 the Author(s). Published by PNAS.

Déclaration de conflit d'intérêts

The authors declare no competing interest.

Références

Nat Commun. 2021 Jan 11;12(1):267
pubmed: 33431879
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
JAMA Netw Open. 2021 Jan 4;4(1):e2035057
pubmed: 33410879
Clin Microbiol Rev. 2001 Oct;14(4):778-809, table of contents
pubmed: 11585785
J Clin Med. 2021 Jan 17;10(2):
pubmed: 33477365
Sci Adv. 2020 Nov 20;6(47):
pubmed: 33097472
PLoS Comput Biol. 2012;8(6):e1002588
pubmed: 22761567
Ann Intern Med. 2020 Aug 18;173(4):262-267
pubmed: 32422057
J Virol. 2006 Aug;80(15):7590-9
pubmed: 16840338
PLoS Comput Biol. 2007 Dec;3(12):e240
pubmed: 18069885
Elife. 2021 Sep 27;10:
pubmed: 34569939
Science. 2020 Aug 28;369(6507):1106-1109
pubmed: 32694200
N Engl J Med. 2020 Aug 27;383(9):885-886
pubmed: 32530584
Science. 2006 May 12;312(5775):879-82
pubmed: 16690858
Elife. 2021 Feb 23;10:
pubmed: 33620317
Philos Trans R Soc Lond B Biol Sci. 2015 Aug 19;370(1675):
pubmed: 26150668
Clin Infect Dis. 2020 Dec 31;71(11):2927-2932
pubmed: 32594116
N Engl J Med. 2020 May 28;382(22):2158-2160
pubmed: 32329972
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
Emerg Infect Dis. 2020 Aug;26(8):1924-1926
pubmed: 32453686
PLoS Biol. 2021 Jul 12;19(7):e3001333
pubmed: 34252080
J Virol. 2010 Apr;84(8):3974-83
pubmed: 20130053
PLoS Comput Biol. 2021 Mar 1;17(3):e1008752
pubmed: 33647008
JAMA Netw Open. 2020 Jul 1;3(7):e2016818
pubmed: 32735339
Open Forum Infect Dis. 2022 Apr 13;9(7):ofac192
pubmed: 35791353
Science. 2021 Jul 9;373(6551):
pubmed: 34035154
N Engl J Med. 2020 Mar 19;382(12):1177-1179
pubmed: 32074444
JAMA Intern Med. 2020 Sep 1;180(9):1156-1163
pubmed: 32356867
Ann Intern Med. 2020 Dec 1;173(11):879-887
pubmed: 32790510
N Engl J Med. 2020 Nov 26;383(22):e120
pubmed: 32997903
N Engl J Med. 2021 Dec 23;385(26):2489-2491
pubmed: 34941024
N Engl J Med. 2020 May 28;382(22):2081-2090
pubmed: 32329971
Indoor Air. 2010 Feb;20(1):2-16
pubmed: 19874402
CPT Pharmacometrics Syst Pharmacol. 2020 Sep;9(9):509-514
pubmed: 32558354
Clin Infect Dis. 2021 Jun 1;72(11):e921
pubmed: 32986798
J Theor Biol. 2021 May 21;517:110621
pubmed: 33587929
Emerg Infect Dis. 2020 Nov;26(11):2701-2704
pubmed: 32749957
Proc Natl Acad Sci U S A. 2021 Feb 23;118(8):
pubmed: 33536313
Nat Med. 2020 May;26(5):672-675
pubmed: 32296168
Proc Natl Acad Sci U S A. 2020 Jun 2;117(22):11875-11877
pubmed: 32404416
Nat Med. 2021 May;27(5):790-792
pubmed: 33782619
Lancet Infect Dis. 2020 Aug;20(8):920-928
pubmed: 32422201
Immunol Rev. 2018 Sep;285(1):81-96
pubmed: 30129207
J R Soc Interface. 2020 Jul;17(168):20200144
pubmed: 32693748
PLoS Med. 2008 Mar 25;5(3):e74
pubmed: 18366252
Proc Natl Acad Sci U S A. 2007 Oct 30;104(44):17441-6
pubmed: 17954909
J Pediatr. 2020 Dec;227:45-52.e5
pubmed: 32827525
Sci Adv. 2021 Jan 1;7(1):
pubmed: 33219112
J Clin Virol. 2022 Jun;150-151:105151
pubmed: 35398602

Auteurs

Ruian Ke (R)

Theoretical Biology and Biophysics Group, Theoretical Division, Los Alamos National Laboratory, Los Alamos, NM 87545.
New Mexico Consortium, Los Alamos, NM 87544.

Carolin Zitzmann (C)

Theoretical Biology and Biophysics Group, Theoretical Division, Los Alamos National Laboratory, Los Alamos, NM 87545.

David D Ho (DD)

Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032.

Ruy M Ribeiro (RM)

Theoretical Biology and Biophysics Group, Theoretical Division, Los Alamos National Laboratory, Los Alamos, NM 87545.

Alan S Perelson (AS)

Theoretical Biology and Biophysics Group, Theoretical Division, Los Alamos National Laboratory, Los Alamos, NM 87545; asp@lanl.gov.
New Mexico Consortium, Los Alamos, NM 87544.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH